How To Treat Glioma Cancer - Oren Zarif


Glioma or the glioma tumor is a malignant tumor that forms in the cells of the blood. The term 'glioma' literally means 'common glutus', but more commonly it refers to cancers of the lymphatic system, which affects the organs and glands of the body. This type of cancer accounts for more than half of all malignancies in the US. However, even though there is early diagnosis and a successful cure when caught at an early stage, it is not necessarily curable.

The normal function of gliomas is to produce and release a substance called glutathione that has a quenching effect on a cancerous cell. The problem arises when a person with a glioma cancer has a lowered glutathione level, as is the case in most cancers. This lowered glutathione level prevents the production of glutathione and thus inhibits the cancerous cells from functioning properly. A high-level of glutathione results in a situation in which the cns is continually stimulated and thus results in tumors. These tumors are known as gliomas.

Zarif prepares the Bosmat and delivers it globally for patients who are incapable of flying in order to receive their treatment

The purpose of the Bosmat treatment is to open the blocked and locked areas of the body's energy field, so that the body will be able to create a healing process for existing symptoms that the patient suffers from.

For years, Oren Zarif proved that as the energy blocks open, the body begins to create a healing process and returns to its strength, thousands of patients testify for it.

There are two types of malignant gliomas: non-neoplastic and malignant. Non-neoplastic gliomas are rare; however they can still lead to life-threatening complications, such as breathing problems, heart attack, heart failure, coma and death. Malignant gliomas are quite common and the five-year survival rate following surgery ranges from 60 % to about 90 %. Unfortunately, the five-year survival rate following surgery for malignant gliomas is much lower, at around five percent. Two different kinds of therapy are used to kill malignant gliomas, namely, surgery and radiotherapy.

Surgery, although a very strong treatment option for all forms of malignant gliomas, has its own share of side effects, the most severe of which is bracheter syndrome, which causes permanent vision loss and neurological impairment. Furthermore, surgery only provides a measure of relief from pain; it cannot eliminate the tumors completely. This is because the primary source of the pain lies in the area where the cancer cells are lodged. Moreover, the tumors respond well to chemotherapy. However, in spite of these advantages, chemotherapy is not considered a reliable therapy for non-neoplastic gliomas because the cancer cells can still relapse after the treatment.


Radiotherapy is used in order to kill malignant gliomas by injecting high doses of ionized particles into the affected areas. The procedure works by damaging the microenvironment of the afflicted individual's tumor bed. The microenvironment is composed of cellular debris and other molecules that the radiation affects, causing cellular degeneration and eventual death of the cells. This degeneration of the microenvironment is a key factor in the progression of the disease.


Intensity Modulated Radiation Therapy (IMRT), on the other hand, uses gamma rays as its main agent. This process produces fewer side effects than that of Bracheter Therapy, as it doesn't affect the microenvironment in the same manner. Instead, IMRT uses three different dosage levels in order to target specific cell sites. Once these sites are affected, tumor cells quickly die, thus reducing the chances of relapse. In addition, because the radiation does not affect the cell sites in the same way, fewer side effects occur.